Title |
Cannabinoids in the management of spasticity associated with multiple sclerosis
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, August 2008
|
DOI | 10.2147/ndt.s3208 |
Pubmed ID | |
Authors |
Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco |
Abstract |
The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 25% |
Switzerland | 1 | 13% |
Ireland | 1 | 13% |
Unknown | 4 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 88% |
Scientists | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 2% |
Ireland | 1 | 1% |
Unknown | 91 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 13% |
Student > Master | 12 | 13% |
Student > Bachelor | 11 | 12% |
Student > Ph. D. Student | 8 | 9% |
Other | 7 | 7% |
Other | 21 | 22% |
Unknown | 23 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 29% |
Biochemistry, Genetics and Molecular Biology | 8 | 9% |
Neuroscience | 7 | 7% |
Agricultural and Biological Sciences | 6 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Other | 14 | 15% |
Unknown | 27 | 29% |